octurnal supplemental oxygen for obstructive sleep apnoea in patients with fibrotic interstitial lung disease

Not Applicable

Recruiting

• Conditions: Interstitial lung disease; Obstructive sleep apnoea; Respiratory - Other respiratory disorders / diseases; Respiratory - Sleep apnoea

• Registration Number: ACTRN12621001109897
• Lead Sponsor: Dr Yet Hong Khor

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-23
• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

1.Age greater than or equal to 18 years
2.Able to give written informed consent
3.A multidisciplinary diagnosis of fibrotic interstitial lung disease of any aetiology
4.Suspected obstructive sleep apnoea or confirmed diagnosis of obstructive sleep apnoea using overnight polysomnography

Exclusion Criteria

1.Use of or eligible for long-term oxygen therapy
2.Use of respiratory stimulants or depressants
3.Stable health condition (defined as hospitalisation for acute medical conditions) in the last 4 weeks before screening
4.Significant co-existing chronic obstructive pulmonary disease (defined as FEV1/FVC <60% on the most recent lung spirometry or extent of emphysema greater than extent of fibrosis on the most recent CT chest)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Apnoea-hypopnoea index measured by overnight polysomnography[ During each night of intervention and control exposure];Apnoea-hypopnoea index without desaturation (i.e. flow-based apnoea-hypopnoea index) measured by overnight polysomnography[ During each night of intervention and control exposure]